

| Package | Price per Dose | Price | |
|---|---|---|---|
| 180 pills | C$11.86 | C$2,845.21 C$2,133.91 Free shipping | |
| 120 pills | C$12.06 | C$1,928.95 C$1,446.71 Free shipping | |
| 90 pills | C$12.26 | C$1,470.82 C$1,103.11 Free shipping | |
| 60 pills | C$12.46 | C$996.61 C$747.46 Free shipping | |
| 30 pills | C$12.66 | C$506.33 C$379.75 Free shipping | |
| 20 pills | C$12.86 | C$342.90 C$257.18 | |
| 10 pills | C$13.06 | C$174.12 C$130.59 | |
| 120 pills | C$15.71 | C$2,513.00 C$1,884.75 Free shipping | |
| 90 pills | C$15.99 | C$1,918.23 C$1,438.67 Free shipping | |
| 60 pills | C$16.28 | C$1,302.03 C$976.52 Free shipping | |
| 30 pills | C$16.42 | C$656.36 C$492.27 Free shipping | |
| 20 pills | C$16.58 | C$442.03 C$331.52 Free shipping | |
| 10 pills | C$16.68 | C$222.34 C$166.76 |
Disclaimer: This information is intended to support, not replace, the advice provided by a healthcare professional. It should be used together with the official patient information leaflet supplied with the medicine.
Hyponatremia is an electrolyte disturbance characterized by a low concentration of sodium in the blood, a condition that can accompany several illnesses and hospitalisations. Studies suggest it is a frequent issue in clinical practice, particularly among patients with fluid balance disorders and certain hormonal problems. Tolvaptan, the active ingredient in Samsca, belongs to the drug class known as vasopressin receptor antagonists (V2 receptor blockers). These medicines are designed to correct low blood sodium by promoting the excretion of free water without substantial loss of electrolytes. The resulting aquaresis can help restore a safer sodium level in the blood.
The brand name Samsca is used in Canada for this medication; the generic name tolvaptan is also widely recognized. This drug is supplied as orally administered tablets for daily use, and may require a prescription depending on local rules. The intended purpose is to treat hyponatremia that is associated with certain conditions, where fluid balance has contributed to low serum sodium. The product leaflet should be consulted for country-specific details and safety information. In all circumstances, the medication should be used under the supervision of a healthcare professional.
In clinical practice, the goal of therapy is to correct serum sodium carefully and safely, avoiding too-rapid changes that may carry risks. Careful monitoring is essential during treatment, including serial measurements of blood sodium and assessment of volume status. If there is any uncertainty about use, a pharmacist or physician should be consulted for guidance and to review potential drug interactions. The safety profile will be discussed with the patient by the prescribing clinician before starting therapy.
In terms of patient safety, it is important to recognise that Samsca does not replace saline infusions or other therapies in every setting. It serves a specific role when hyponatremia is linked to impaired water excretion rather than to a deficit of body sodium alone. The decision to initiate therapy should consider the underlying cause of hyponatremia, current fluid status, and the risks associated with rapid shifts in sodium levels. The official patient information leaflet provides country-specific guidance and warnings that must be followed closely.
Tolvaptan is indicated for hyponatremia (low blood sodium) arising from certain conditions where excess body water dilutes serum sodium. The most common scenarios include hyponatremia associated with the syndrome of inappropriate antidiuretic hormone secretion (SIADH), heart failure with preserved or reduced ejection fraction, and cirrhosis with ascites contributing to low sodium. These conditions are associated with fluid overload or abnormal hormone signals that retain water in the body, diluting sodium in the bloodstream. The medication aims to restore sodium balance while preserving essential electrolytes.
Symptoms of hyponatremia can include confusion, lethargy, muscle cramps, headaches, nausea, and in severe cases seizures or coma. These symptoms may reflect a dangerous drop in serum sodium and require urgent medical evaluation. In the setting of Samsca therapy, ongoing assessment of neurological status and fluid balance is important, particularly at the start of treatment or after dose changes. If new symptoms emerge or if there is worsening confusion or seizures, medical attention should be sought promptly.
The scope of use is limited to hyponatremia that is associated with the conditions mentioned above, and the decision to use Samsca should be based on the overall clinical picture. If the underlying cause of hyponatremia is unknown, or if there is another contributing medical condition, consultation with a healthcare professional is advised. The aim is to optimise sodium levels while avoiding adverse events related to treatment. Long-term dependence on any single therapy should be discussed with the healthcare team to ensure that the approach remains appropriate for the patient’s evolving condition.
In Canada, the availability and use of Samsca may be governed by provincial and national guidelines, and local practice patterns should be consulted. The medication is not intended for routine fluid restriction or as a general diuretic replacement. A healthcare professional will determine whether to initiate, continue, or discontinue therapy based on response and safety considerations. If a patient has questions about whether their specific diagnosis qualifies for Samsca, confirmation with a clinician is recommended.
Tolvaptan acts as a selective antagonist of the vasopressin type 2 (V2) receptor on the kidney collecting ducts. By blocking the action of vasopressin (antidiuretic hormone), water reabsorption in the kidney is reduced. This results in increased excretion of free water (aquaresis) without significant loss of electrolytes such as sodium, potassium, or chloride. The net effect is a rise in serum sodium concentration as excess water is removed from the body.
The aquaretic effect is distinct from diuresis, which involves loss of both water and solutes. Because Samsca promotes water loss without a proportionate loss of salts, electrolyte balance is gradually corrected rather than rapidly depleted of other ions. This mechanism supports a safer correction of hyponatremia when fluid excess is contributing to the low sodium level. The widespread clinical implication is improved neurologic function and reduced risk of hyponatremia-associated complications when therapy is properly monitored.
Pharmacokinetic considerations include oral absorption with systemic distribution, hepatic metabolism, and renal excretion. The relationship between dose, plasma concentration, and aquaretic effect informs clinical use, with attention to potential drug interactions that may alter exposure. The official guidance recommends careful dose titration and monitoring of serum sodium to maintain safe correction rates. If any uncertainties arise regarding mechanism or expected response, consult the official leaflet or a healthcare professional for clarification.
In practice, the mechanism translates to a targeted intervention for water handling in the kidneys, aligning treatment with the underlying pathophysiology of hyponatremia in the listed conditions. The result is a physiologic shift toward higher serum sodium as water balance normalises under supervision. Patient education should emphasise that improvement in symptoms may not be immediate and that adherence to monitoring schedules is essential for safety and efficacy.
The exact dosage and duration must be determined by a clinician, with adjustments based on response and laboratory results. A fixed dosing regimen is not appropriate for all patients, and prescription practices vary by region. If a dose is missed, the standard approach is to resume the regular schedule as soon as it is remembered unless the next dose is due shortly; in that case, skip the missed dose and continue with the planned timetable. Do not double-dose to make up for a missed administration.
Take Samsca exactly as prescribed. Tablets are intended for oral use and may be taken with or without food, unless the prescribing clinician or product leaflet provides specific instructions. The time of day should be kept as consistent as possible to maintain a steady exposure and predictable therapeutic effect. Do not abruptly discontinue therapy without consulting a healthcare professional, as a gradual plan is typically preferred to minimise the risk of rebound hyponatremia.
Prior to initiation, a healthcare professional will review potential interactions with other medications, including over‑the‑counter products, vitamins, and herbal supplements. If bleeding, dehydration, or electrolyte disturbances occur, it is essential to report these promptly as adjustments to therapy may be required. The safety panel will include monitoring liver function tests in line with country-specific recommendations, particularly for long-term use. If uncertainty exists regarding dosing or the need for ongoing therapy, contact a pharmacist for guidance.
During treatment, regular laboratory testing and clinical assessment are expected to verify that serum sodium remains within a safe range and that fluid balance remains appropriate. If any new medical condition arises, such as kidney or liver problems, or if there is a plan to start a new medication, the healthcare team should be notified to reassess the treatment plan. The aim is to maintain a controlled correction of sodium while preventing adverse events associated with rapid shifts in osmolality.
Contraindications are conditions or factors that would make Samsca unsuitable for a patient. These can include known hypersensitivity to tolvaptan or any component of the formulation. Known hypersensitivity reactions may present as rash, swelling, or breathing difficulties and require immediate medical attention. The patient information leaflet will list all components and potential allergens. If there is a history of allergic reaction to this medication, a clinician should be consulted before use.
Other contraindications include anuria (the complete absence of urine production) and significant liver disease or impairment in the context of hyponatremia management. In such cases, the risk of adverse effects may outweigh potential benefits, and alternative therapies should be considered. The prescribing clinician will determine suitability based on the clinical picture and safety considerations. If any of these conditions are present or suspected, contact a healthcare professional before starting therapy.
Additional contraindications may cover interactions with other medicines or conditions that could elevate the risk of overly rapid sodium correction or hepatic injury. A thorough medication history helps to identify potential contraindications. If there is doubt about the suitability of Samsca in a specific scenario, the official leaflet and a pharmacist should be consulted to review alternatives.
In all cases, if the patient is pregnant, breastfeeding, or planning pregnancy, the risk–benefit balance must be discussed with a clinician before initiating therapy. Pregnancy and lactation considerations will be addressed in the pregnancy/breastfeeding section. If contraindications are suspected or confirmed, treatment should not commence until professional guidance is obtained.
Warnings describe important safety concerns that require monitoring during therapy. The most critical risk is overcorrection of serum sodium, which can lead to serious neurological complications. Careful monitoring of serum sodium levels, fluid status, and urinary output is essential, particularly during the initial days of treatment or after dose adjustments. If rapid changes are observed, the treatment plan may need to be modified to reduce the risk of harm.
Another key precaution involves liver safety. Some patients may experience elevations in liver enzymes or other signs of hepatic stress during therapy, and liver function tests may be recommended at defined intervals. The patient should be advised to seek urgent medical care if symptoms suggesting liver injury appear, such as persistent abdominal pain, unexplained dark urine, yellowing of the skin or eyes, or persistent nausea or vomiting. If significant liver concerns arise, discontinuation of therapy may be considered.
Volume status and hydration are also central considerations. Excessive water loss can cause dehydration and electrolyte disturbances, while inadequate water loss may fail to correct hyponatremia. Patients should report symptoms such as excessive thirst, dry mouth, dizziness, or persistent confusion. The clinician may adjust fluid intake and dosing accordingly to maintain a safe balance. If there is any doubt about hydration or safety, contact a pharmacist or physician for guidance.
Additional precautions include interactions with medications that affect liver enzymes or water balance. Certain medicines may alter tolvaptan levels and influence the rate of sodium correction. The patient should inform every healthcare provider about all medicines, including herbal products and nonprescription drugs, to avoid adverse interactions. If a planned procedure or hospital admission occurs, the medical team should be informed of Samsca therapy to enable appropriate monitoring and adjustments.
Common side effects are usually mild to moderate and may include thirst, increased urination (polyuria), dry mouth, and dizziness. Nausea, constipation, and fatigue can also occur. Most side effects are manageable and tend to improve with time or dose adjustments under medical supervision. Any persistent or troublesome side effects should be discussed with a pharmacist or clinician.
Serious adverse events are less common but require prompt medical attention. Symptoms such as severe confusion, seizures, marked lethargy, rapid changes in swelling or water balance, or signs of liver injury need urgent evaluation. The patient leaflet provides a list of warning signs that should trigger medical contact. If there is any concern about the severity of a side effect, contact a healthcare professional promptly.
Long-term therapy may be associated with hepatic concerns in some individuals, and regular monitoring is advised to detect early signs of liver stress. If abnormal liver function tests occur, the clinician may choose to adjust the dose or discontinue therapy. Allergic reactions, although rare, would necessitate immediate medical care and a review of alternative treatments.
Because individual responses vary, the appearance and timing of side effects can differ. If multiple symptoms appear together or if adverse effects interfere with daily activities, professional guidance should be sought. The aim is to balance therapeutic benefits with safety considerations and to tailor management to the patient’s needs.
Medicines that affect liver enzymes or water balance can alter how Samsca behaves in the body. Interactions with strong CYP3A inhibitors or inducers, in particular, may change plasma levels of tolvaptan and the rate of sodium correction. A comprehensive list of current medications will help the clinician assess potential interactions. The patient should inform the pharmacist about all prescribed drugs, over-the-counter products, and supplements.
Some diuretics or medications affecting sodium and water handling may interact with Samsca. Co-administration with other agents used to treat hyponatremia or to manage fluid status requires careful monitoring. Food does not usually cause a major change in absorption, but advice on timing with meals may be provided by the clinician depending on the overall treatment plan. Any planned changes to therapy should involve a healthcare professional.
Alcohol consumption and certain herbal products can influence hydration status and overall safety during hyponatremia treatment. The patient should be advised to discuss alcohol use with the healthcare team and to avoid self-adjustment of dosing based on anecdotal information. If a drug interaction is suspected, contact a pharmacist for guidance before continuing or changing therapy. A review of all interactions should be part of ongoing care.
The official patient information for Samsca will include a detailed interactions section. If any new medications are prescribed by any clinician, a review of potential interactions should be requested to determine whether adjustments are warranted. This helps to maintain a safe and effective treatment course.
The safety of tolvaptan in pregnancy has not been established in all cases. It may pose risk to a developing fetus and should only be used during pregnancy if the expected benefit justifies the potential risk. If pregnancy is planned or suspected during therapy, a clinician should be consulted promptly to review options and monitoring needs. Effective contraception discussions may be part of the care plan in patients of childbearing potential.
Breastfeeding while taking Samsca is not well established. It is likely that tolvaptan or its metabolites could pass into breast milk, possibly affecting a nursing infant. If breastfeeding is planned or ongoing, a discussion with a healthcare professional is advised to weigh risks and alternatives. A decision should be made collaboratively, considering maternal health and infant safety.
In any pregnancy-related scenario, stopping therapy or adjusting the dose must be guided by a clinician. If the patient becomes pregnant during treatment, or if there is an intention to breastfeed, contact a pharmacist or physician for tailored guidance. The official leaflets provide country-specific recommendations that should be consulted for the most accurate information.
When planning pregnancy or lactation, the healthcare team considers the overall benefits and risks of continuing Samsca versus alternative treatments. If there are no safe alternatives, a carefully monitored plan may be developed. All decisions should be documented and communicated among the care team for safety and continuity of care.
Yes, Samsca is used in certain hyponatremia cases, including those related to SIADH, when a clinician determines that the benefits outweigh the risks. The decision depends on the underlying cause, patient health, and monitoring capacity. Consultation with a healthcare professional is advised to confirm suitability for the specific situation.
If a dose is missed, take it as soon as it is remembered unless it is almost time for the next dose. Do not double dose to make up for a missed one. When in doubt, contact a pharmacist or clinician for guidance. Do not alter the schedule without professional advice.
Tablets may be taken with or without food unless otherwise instructed. It is important to maintain consistent dosing times and to avoid self-adjusting the amount taken. If there are dietary restrictions or concerns about interactions with beverages, a clinician should be consulted.
Improvements in serum sodium can occur over hours to days, with the pace depending on individual factors and baseline sodium levels. The monitoring plan will guide expectations and safety precautions. Persistent questions about timing should be addressed with the prescribing clinician or pharmacist.
Long-term safety has been studied in certain contexts, but ongoing use requires regular evaluation by a clinician. Liver function and electrolyte balance are among the factors monitored. If liver concerns or persistent adverse effects arise, a clinician may adjust or discontinue therapy.
Any suspected interaction should be discussed with a pharmacist or clinician as soon as possible. A dose adjustment or a change in therapy may be necessary to maintain safety and efficacy. Do not discontinue a medication abruptly without professional advice.
Consultation with a clinician is essential if pregnancy or breastfeeding is possible or planned. The decision depends on balancing potential risks to the fetus or infant with the benefits to the mother's health. It is important to follow professional guidance in these circumstances.
The frequency of liver tests is determined by country-specific guidelines and the clinician’s assessment. Regular monitoring may begin soon after therapy initiation and continue periodically based on risk factors. Abnormal results or symptoms prompt a change in management.
Any signs of dehydration, dizziness, severe thirst, confusion, or seizures require urgent medical evaluation. The care team may adjust fluid intake or dosing in response to such symptoms. Seek prompt professional advice if these symptoms occur.
Yes, regular follow-up is typically required to monitor serum sodium, fluid status, and liver function. Monitoring frequency is tailored to the individual and may change over time. The patient should adhere to all follow-up appointments and testing schedules advised by the clinician.
Inform the hospital team about Samsca therapy so appropriate monitoring can be performed. In emergency situations, healthcare providers should be alerted to the potential for altered water balance and electrolyte changes. Co-management with the prescribing clinician is encouraged.
Official leaflets supplied with the medicine contain patient-specific information, including contraindications, warnings, and dosing guidance. Additional information can be obtained from a pharmacist or the prescribing clinician, who can explain country-specific regulations and recommendations. The patient should consult these sources if questions arise.
Reliable information about Samsca is available in the official patient information leaflet supplied with the product and in the country-specific product monograph. The leaflet includes detailed instructions on indications, contraindications, dosing, monitoring, and safety warnings. Patients should read it carefully and refer to it whenever questions arise. If any point is unclear, a pharmacist or clinician should be contacted for clarification.
Healthcare providers, including physicians and pharmacists, can offer personalised guidance based on medical history and current treatments. They can review potential drug interactions, assess liver function safety, and determine the appropriateness of continuing therapy. Patients are encouraged to maintain open communication with the care team and to report any new symptoms or concerns promptly.
In Canada, access to Samsca may vary by province and by local health authority rules. The official leaflets used in practice reflect national and regional guidelines, and they should be consulted for the most accurate information. When questions arise about eligibility, safety, or alternatives, the pharmacist is available to provide objective, evidence-based counsel. The aim is to support informed decision making and safe, effective use of the medicine.
The patient information package should be retained for future reference. If a patient needs more information, contact the pharmacy team or the prescribing clinician. Reassessment of the treatment plan is recommended at scheduled intervals or sooner if circumstances change, to ensure that the therapy continues to meet safety and therapeutic goals.
14–21 days. Free from C$287.05 .
5–9 days. C$43.06
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
